Brentuximab Vedotin Plus Chemo Is Effective and Tolerable in Patients with Early-Stage Hodgkin Lymphoma
Treating patients with brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy resulted in strong efficacy and encouraging tolerability in early-stage, unfavorable-risk Hodgkin lymphoma.
Radiation Therapy Improves Survival in Hodgkin's Lymphoma
Despite a recent decline in utilization, consolidated radiation therapy (RT) has been shown to improve 10-year survival rates for patients with stage I/II Hodgkin's lymphoma following treatment with chemotherapy.
Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer
GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
